BMS 986090

Drug Profile

BMS 986090

Alternative Names: Anti-CD40 dab; Anti-CD40 monoclonal antibody - BMS; BMS-986090

Latest Information Update: 12 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Monoclonal antibodies
  • Mechanism of Action CD40 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Immunological disorders

Most Recent Events

  • 30 Mar 2016 Bristol-Myers Squibb terminates a phase I trial in healthy volunteers in USA (NCT02079480)
  • 01 May 2014 Phase-I clinical trials in Immunological disorders (in volunteers) in USA (IV)
  • 01 May 2014 Phase-I clinical trials in Immunological disorders (in volunteers) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top